In pediatric B-ALL, Ott et al. first demonstrated the therapeutic potential of the BET inhibitor JQ1, which downregulated MYC and IL7R, disrupted the CRLF2–IL7R–JAK–STAT axis, and improved xenograft survival [67]. This evidence concerns the gene IL7R and precursor B-cell acute lymphoblastic leukemia.